Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
In Depth
LGS accounts for 1–4% of childhood epilepsies and is notoriously treatment-resistant. Along with Dravet syndrome, LGS is one of two FDA-approved indications for Epidiolex (CBD). The pivotal GWPCARE3 and GWPCARE4 trials demonstrated significant reductions in drop seizure frequency with CBD vs. placebo. CBD's mechanism in epilepsy may involve sodium channel modulation, GPR55 antagonism, and reduction of neuronal hyperexcitability.
Related Terms
Further Reading
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.
Nabiximols (Sativex)
A whole-plant cannabis extract containing a 1:1 ratio of THC:CBD, delivered as an oromucosal spray. Approved in over 30 countries for multiple sclerosis spasticity.